title: [Benefits of spironolactone as the optimal treatment for drug resistant hypertension. Pathway-2 trial review].
abstract: Pathway-2 is the first randomised, double-blind and crossover trial that compares spironolactone as a fourth drug with alfa-blocker, beta-blocker and placebo. This study shows that spironolactone is the drug with more possibilities of success for the management of patients with difficult-to-treat hypertension in patients with a combination of three drugs and poor control. The results validate the widespread treatment with mineralocorticoid receptor antagonists in resistant hypertension.
authors.affiliation: Unidad de Hipertensión, Servicio de Nefrología, Hospital Universitario 12 de Octubre, Madrid, España. Electronic address: josecarlos.prado@salud.madrid.org.
authors.forename: J C
authors.initials: JC
authors.lastname: Prado
authors.affiliation: Instituto de Investigación i+12, Hospital Universitario 12 de Octubre, Madrid, España.
authors.forename: L M
authors.initials: LM
authors.lastname: Ruilope
authors.affiliation: Unidad de Hipertensión, Servicio de Nefrología, Hospital Universitario 12 de Octubre, Madrid, España.
authors.forename: J
authors.initials: J
authors.lastname: Segura
mesh_terms: D017298:Bisoprolol; D018592:Cross-Over Studies; D004311:Double-Blind Method; D017292:Doxazosin; D006801:Humans; D006973:Hypertension; D013148:Spironolactone
chemical_list: D013148:Spironolactone; D017292:Doxazosin; D017298:Bisoprolol
keywords: Antagonistas del receptor de mineralocorticoides; Denervación renal; Espironolactona; Hipertensión arterial resistente; Mineralocorticoid receptor antagonists; Renal denervation; Resistant hypertension; Spironolactone